Israeli Start-Ups Will Benefit from the New FDA Policy

Co-chair of the firm's Israel Practice Meital Stavinsky wrote an article on a recent statement made by the U.S. Food and Drug Administration (FDA) and the Center for Biological Research and Development (CBER) in favor of policies that support the development of products for the treatment of cells and genes. She explains how Israeli people have been at the forefront of discovering many of these breakthrough medicines and speculates that in the near future more and more FDA-approved products will come to fruition.

READ: Israeli Start-Ups Will Benefit from the New FDA Policy